Stocksigma LogoStocksigma Logo

RPG Life Sciences Reports Strong H1 FY27 Growth and API Expansion

RPG Life Sciences reported a 16.2% YoY increase in revenue from operations to ₹407.3 cr for H1 FY27, with adjusted EBITDA rising 16.1% YoY to ₹97.9 cr

RPG Life Sciences Reports Strong H1 FY27 Growth and API Expansion

RPG Life Sciences Ltd · Investor Presentation · 30 Oct 2026, 4:54 am

RPG Life Sciences Reports Strong H1 FY27 Growth and API Expansion RPG Life Sciences reported a 16.2% YoY increase in revenue from operations to ₹407.3 cr for H1 FY27, with adjusted EBITDA rising 16.1% YoY to ₹97.9 cr (24.0% margin) and adjusted PAT growing 14.8% YoY to ₹62.9 cr. Segmentally, Domestic Formulations grew 13.0% YoY to ₹278.3 cr, International Formulations rose 7.0% YoY to ₹71.7 cr, and API surged 58.5% YoY to ₹54.6 cr. The company established dedicated subsidiary RPG Active Pharma, partnering with InvAscent with a ₹700 cr capital pool, and acquired Actis and Raghava Life Sciences.

Original exchange filing (PDF)

More announcements from RPG Life Sciences Ltd

All RPG Life Sciences Ltd announcements